You are here

Lipids & Metabolic

 

Researchers have identified a gene, called MeXis, that helps remove cholesterol from blood vessels. Senior study author Peter Tontonoz, MD, PhD, and colleagues found mice lacking MeXis had nearly twice as many blockages in their blood vessels as those that had normal levels of the gene.

Abbott announced Feb. 7 the FreeStyle LibreLink smartphone application—to be used alongside the company’s continuous glucose monitor—is now available to iPhone and Android users in 12 European countries.

According to a meta-analysis in the European Journal of Preventive Cardiology, a 143-pound person could burn an additional 54 calories by standing instead of sitting for six hours. Assuming food intake remained steady, that would translate to a loss of 5.5 pounds over the course of a year.

National guidelines recommend teens aim for an hour of moderate to vigorous exercise per day to maintain good health and ensure future wellbeing, but researchers at the University of Exeter in the United Kingdom are saying that might not cut it.

A new study is enrolling patients to evaluate whether bariatric surgery—normally reserved for the severely obese—is beneficial in a lighter subset of patients.

 

Recent Headlines

Most commonly prescribed diabetes drug also least likely to be taken

One-third of diabetic patients prescribed metformin—the mostly commonly recommended diabetes drug—aren’t taking the medication due to side effects ranging from diarrhea to depression, researchers in the United Kingdom have found.

Living near gyms—and away from fast food—tied to smaller waistlines

A new study out of the United Kingdom suggests people truly are products of their environments—at least when it comes to developing obesity.

Diabetic children have 7 times greater risk of cardiac death than peers

Children with diabetes are seven times more likely to experience sudden cardiac death than their non-diabetic peers, according to research reported by the American Heart Association this week.

Researchers debunk claim that obesity improves end-of-life survival for CVD patients

Cardiovascular disease’s “obesity paradox”—the idea that being dangerously overweight can improve end-of-life survival in heart patients—was recently debunked by a team of researchers in New York and Michigan, finding the claim to be untrue for those with incident heart disease.

Gastric bypass patients sustain long-term weight loss, comorbidity reduction

A majority of patients who undergo bariatric surgery for the first time maintain significant weight loss through seven years of follow-up, according to a study published Dec. 6 in JAMA Surgery.

Commonly prescribed painkillers raise risk of obesity, hypertension

Commonly prescribed analgesic drugs, including opiates and certain antidepressants, could be doing more harm than good, according to a study published in PLOS One this week. Not only can these addictive pain medications cause sedation, disordered breathing and accidental overdoses, but they reflect poorly on a patient’s cardiometabolic profile and increase risks of developing obesity and hypertension.

Hot flashes can increase a woman's risk of diabetes by 18%

Hot flashes—especially those accompanied by night sweats—could be not only a routine symptom of menopause but also a precursor to diabetes, according to a study published this week in Menopause, the journal of the North American Menopause Society (NAMS).

High BMI linked to dementia decades down the road

Higher body mass index (BMI) in middle age could be a warning sign of dementia decades down the road, scientists reported this week, but weight loss leading up to a formal diagnosis could mask symptoms and confound patients.

Based on current trends, 57% of US children will be obese at age 35

More than half of U.S. children will be obese at age 35, according to a study published in the New England Journal of Medicine.

FDA approves evolocumab to prevent heart attack and stroke

The FDA has approved Amgen’s evolocumab (Repatha) for the prevention of strokes, heart attacks and coronary revascularizations—the first PCSK9 inhibitor to gain approval for such a broad number of indications.

Pages